In patients with idiopathic pulmonary fibrosis (IPF), the effects of antifibrotic agents on the
prognosis remain unclear. This study aimed to investigate the impact of antifibrotic treatment …

Background Idiopathic pulmonary fibrosis (IPF) is a progressive fibrosing interstitial lung
disease associated with significant morbidity and mortality. Nintedanib and pirfenidone are …

In addition to facilitating healthcare delivery planning, reliable information about prognosis is
essential for treatment decisions in patients with idiopathic pulmonary fibrosis (IPF). This …

Background Patients with idiopathic pulmonary fibrosis (IPF) frequently have multiple
comorbidities, which may influence survival but go under-recognised in clinical practice. We …

Objective There is a paucity of observational data on antifibrotic therapy for idiopathic
pulmonary fibrosis (IPF). We aimed to assess the course of disease of IPF patients with and …

Rationale: In recent decades, diagnosis and treatment recommendations for idiopathic
pulmonary fibrosis (IPF) have changed. In Korea, the average life expectancy has increased …

Purpose Real-world studies have reported reduced mortality in patients with idiopathic
pulmonary fibrosis (IPF) treated with antifibrotic therapy; however, the initiation or …

BACKGROUND: Additional real-world studies are needed to more fully elucidate the
effectiveness of antifibrotic treatment in slowing the progression of idiopathic pulmonary …

Background There are substantial advances in diagnosis and treatment for idiopathic
pulmonary fibrosis (IPF), but without much evidence available on recent mortality and …

Introduction Idiopathic pulmonary fibrosis (IPF) is the most common of the idiopathic
interstitial pneumonias. It is a serious and progressive lung disease with a median survival …